Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Aptinyx Inc (APTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8164)・商品コード:DATA904C8164
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:31
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Aptinyx Inc. (Aptinyx), formerly Enarex Inc, is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of neurological disorders. The company’s proprietary chemistry platform helps develop a pipeline of small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors and improves synaptic plasticity. Many NMDA receptor modulators are under clinical development as differentiated therapies for depression, and they possess efficacy and safety with the potential to treat various neurologic disorders. The company’s pipeline products include NYX-2925, which is under clinical development as a therapy for neuropathic pain; NYX-783, for post-traumatic stress disorder (PTSD); and NYX-458, for the treatment of cognitive impairment associated with Parkinson’s disease. Aptinyx is headquartered in Evanston, Illinois, the US.

Aptinyx Inc (APTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptinyx Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Aptinyx Raises USD70 Million in Series B Financing 11
Aptinyx Raises USD65 Million in Series A Venture Financing 13
Aptinyx Raises Funds through Seed Financing 15
Partnerships 16
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 16
Aptinyx to Enter into Research Partnership with Allergan 17
Equity Offering 18
Aptinyx Raises USD117.8 Million in IPO of Shares 18
Aptinyx Spin Off from Naurex 20
Aptinyx Inc – Key Competitors 21
Aptinyx Inc – Key Employees 22
Aptinyx Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 14, 2018: Aptinyx announces second quarter 2018 financial results 24
Corporate Communications 26
May 17, 2018: Aptinyx Appoints Robert Hombach to Board of Directors 26
May 03, 2018: Aptinyx Promotes David Houck to Chief Development Officer 27
Feb 13, 2018: Aptinyx Names Ashish Khanna As Chief Financial Officer and Chief Business Officer 28
Dec 07, 2017: Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as Chief Commercial Officer 29
Clinical Trials 30
Mar 15, 2018: Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Aptinyx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aptinyx Raises USD70 Million in Series B Financing 11
Aptinyx Raises USD65 Million in Series A Venture Financing 13
Aptinyx Raises Funds through Seed Financing 15
Allergan Exercises Option to Acquire AGN-241751 from Aptinyx 16
Aptinyx to Enter into Research Partnership with Allergan 17
Aptinyx Raises USD117.8 Million in IPO of Shares 18
Aptinyx Spin Off from Naurex 20
Aptinyx Inc, Key Competitors 21
Aptinyx Inc, Key Employees 22
Aptinyx Inc, Other Locations 23

List of Figures
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aptinyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8164)販売に関する免責事項を必ずご確認ください。
★調査レポート[Aptinyx Inc (APTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆